{"id":"W2136713872","doi":"10.2174/187153010790827993","title":"Imatinib Mesylate (Gleevec©): Targeted Therapy Against Cancer with Immune Properties","year":2010,"lang":"en","type":"review","venue":"Endocrine Metabolic & Immune Disorders - Drug Targets","topic":"Chronic Myeloid Leukemia Treatments","field":"Medicine","cited_by":5,"is_retracted":false,"has_abstract":true,"ca_institutions":"","funders":"Institut National Du Cancer; Ligue Contre le Cancer; Institute of Cancer Research; Institut National de la Santé et de la Recherche Médicale","keywords":"Imatinib mesylate; Imatinib; Medicine; Targeted therapy; Tyrosine kinase; Tyrosine-kinase inhibitor; Cancer research; Immune system; Cancer; Pharmacology; Immunology; Internal medicine; Receptor; Myeloid leukemia","routes":{"ca_aff":false,"ca_fund":true,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":true},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.0001830144,0.0005842981,0.0007600812,0.001142315,0.0001481056,0.0004000335,0.0003164466,0.0004374958,0.002639232],"category_scores_gemma":[0.0001137664,0.0001360284,0.0002100735,0.001155135,0.0001926095,0.0005937478,0.0003662989,0.0008197321,0.00225351],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.0002982202,"about_ca_system_score_gemma":0.00035621,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.0003826687,"about_ca_topic_score_gemma":0.001131127,"domain_scores_codex":[0.9999382,0.000008794803,0.000007776108,0.00001156744,0.00002590076,0.000007770947],"domain_scores_gemma":[0.9999683,0.00001078893,0.000007304639,0.000001255465,0.000006760056,0.000005602285],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"design_other","study_design_gemma":"not_applicable","study_design_scores_codex":[0.0001060042,0.0001006152,0.0001287186,0.005221541,0.00004908611,0.0002565332,0.00003924414,0.0003280567,0.01116965,0.002852304,0.01277169,0.9669766],"study_design_scores_gemma":[0.00004948076,0.0002441128,0.0007969266,0.0005508622,0.0000614239,0.002321237,0.00002983695,0.0001055942,0.003809988,0.001169785,0.9908473,0.00001327253],"study_design_candidate":"not_applicable","study_design_consensus":null,"genre_codex":"review","genre_gemma":"review","genre_scores_codex":[0.001159384,0.9946265,0.0004233784,0.0002777955,0.0001454578,0.00001429775,0.00004739206,0.00002142701,0.003284277],"genre_scores_gemma":[0.003950835,0.992446,0.0005636792,0.0001997561,0.0001156068,0.00001523347,0.00008669899,0.000002797178,0.002619443],"genre_candidate":"review","genre_consensus":"review","teacher_disagreement_score":0.002639232,"threshold_uncertainty_score":0.008829117,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.02049554789560371,"score_gpt":0.2982617519964285,"score_spread":0.2777662041008248,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}